Lek Pharmaceuticals d.d., PharOS Mt Ltd, Rontis Hellas Medical And Pharmaceutical Products S.A.
PolandAll drugs from this manufacturer
-
This medicine is used in adult patients with type 2 diabetes to balance blood sugar levels. It helps increase the amount of insulin released after a meal and reduces the amount of sugar produced by the body.
Dosage form: tablets, film-coated
Active substance Dosage sitagliptin hydrochloride monohydrate 56.7 mg metformin hydrochloride 850 mg ATC: A10BD07
-
This medicine is used in adult patients with type 2 diabetes to help balance blood sugar levels. It works by increasing insulin levels after meals and reducing the amount of sugar produced by the body.
Dosage form: tablets, film-coated
Active substance Dosage sitagliptin hydrochloride monohydrate 56.7 mg metformin hydrochloride 1000 mg ATC: A10BD07
-
This medicine is used in adult patients with type 2 diabetes to reduce high blood sugar levels. It helps increase the level of insulin released after meals and limits the amount of sugar produced by the body.
Dosage form: tablets, film-coated
Active substance Dosage sitagliptin hydrochloride monohydrate 28.34 mg ATC: A10BH01
-
The medicine is used in adult patients with type 2 diabetes to reduce high blood sugar levels. It helps increase the level of insulin released after a meal and limits the amount of sugar produced by the body.
Dosage form: tablets, film-coated
Active substance Dosage sitagliptin hydrochloride monohydrate 56.69 mg ATC: A10BH01
-
This medicine is used to reduce high blood sugar levels in adult patients with type 2 diabetes. It helps increase insulin levels after meals and limits the amount of sugar produced by the body.
Dosage form: tablets, film-coated
Active substance Dosage sitagliptin hydrochloride monohydrate 113.38 mg ATC: A10BH01
-
This medicine is used in adults to reduce the risk of a subsequent heart attack or death from cardiovascular disease (following acute coronary syndrome) and to reduce the risk of blood clots in people with coronary artery disease or peripheral artery disease.
Dosage form: tablets, film-coated
Active substance Dosage rivaroxaban 2.5 mg ATC: B01AF01
-
The medicine is used in adults to prevent the formation of blood clots in the veins following hip or knee replacement surgery. It is also used to treat deep vein thrombosis and pulmonary embolism, as well as to prevent the recurrence of these clots.
Dosage form: tablets, film-coated
Active substance Dosage rivaroxaban 10 mg ATC: B01AF01
-
The medicine is used in adults to prevent strokes and blood clots (in atrial fibrillation) and for the treatment and prevention of deep vein thrombosis and pulmonary embolism. In children and adolescents (weighing more than 30 kg), it is used for the treatment and prevention of venous or pulmonary clots following initial treatment with injections.
Dosage form: tablets, film-coated
Active substance Dosage rivaroxaban 20 mg ATC: B01AF01
-
The medicine is used in adults to treat blood clots in the veins of the legs (deep vein thrombosis) and in the blood vessels of the lungs (pulmonary embolism), as well as to prevent the recurrence of such clots.
Dosage form: tablets, film-coated
Active substance Dosage rivaroxaban 15 mg or 20 mg ATC: B01AF01
-
In adults, it is used to prevent strokes and blood clots (in atrial fibrillation) and for the treatment and prevention of deep vein thrombosis and pulmonary embolism. In children and adolescents (weighing more than 30 kg), it is used for the treatment and prevention of blood clots in the veins or lungs following initial treatment with injections.
Dosage form: tablets, film-coated
Active substance Dosage rivaroxaban 15 mg ATC: B01AF01